STOCK TITAN
  1. Home
  2. Sec-filings
  3. IONS
  4. [Form 4] IONIS PHARMACEUTICALS INC Insider Trading Activity

Ionis Pharmaceuticals (NASDAQ: IONS) director granted 10,753 stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Ionis Pharmaceuticals director Peter N. Reikes received a grant of non-qualified stock options covering 10,753 shares of common stock. The options have an exercise price of $75.13 per share and were awarded under the company’s Amended & Restated 2002 Non-Employee Directors' Stock Option Plan.

The grant vests in three equal annual installments, with the first tranche vesting and becoming exercisable on June 4, 2027, and the options becoming fully vested and exercisable on June 4, 2029. The options expire on June 4, 2036. This is a compensation-related award rather than an open-market purchase or sale.

Positive

  • None.

Negative

  • None.
Insider Reikes Peter N
Role null
Type Security Shares Price Value
Grant/Award Non-Qualified Stock Option (right to buy) 10,753 $0.00 --
Holdings After Transaction: Non-Qualified Stock Option (right to buy) — 10,753 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Option grant size 10,753 options Non-qualified stock option grant to director on June 4, 2026
Exercise price $75.13 per share Exercise price of non-qualified stock options
Vesting start date June 4, 2027 First of three equal annual vesting installments
Full vesting date June 4, 2029 Date when options become fully vested and exercisable
Expiration date June 4, 2036 Option term end for this grant
Non-Qualified Stock Option financial
"Grant of 06/04/2026 to reporting person of stock options under the Ionis Pharmaceuticals, Inc."
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
Amended & Restated 2002 Non-Employee Directors' Stock Option Plan financial
"under the Ionis Pharmaceuticals, Inc. Amended & Restated 2002 Non-Employee Directors' Stock Option Plan."
vests and becomes exercisable financial
"The option vests and becomes exercisable in three equal annual installments, the first installment vesting on 06/04/2027."
exercise price financial
"conversion_or_exercise_price: "75.1300""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Reikes Peter N
(Last)(First)(Middle)
2855 GAZELLE COURT
(Street)
CARLSBAD CALIFORNIA 92010
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
IONIS PHARMACEUTICALS INC [ IONS ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Non-Qualified Stock Option (right to buy)$75.1306/04/2026A10,75306/04/2027(1)06/04/2036(1)Common Stock10,753$0.010,753D
Explanation of Responses:
1. Grant of 06/04/2026 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended & Restated 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in three equal annual installments, the first installment vesting on 06/04/2027. The option shall be fully vested and exercisable on 06/04/2029. The stock option was exercisable as to 0 shares on 06/04/2026.
By: Patrick R. O'Neil, attorney-in-fact For: Peter N. Reikes06/05/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Ionis Pharmaceuticals (IONS) director Peter Reikes report on this Form 4?

Director Peter N. Reikes reported receiving a grant of 10,753 non-qualified stock options. These options relate to Ionis common stock and reflect equity-based director compensation rather than an open-market share purchase or sale.

How many Ionis Pharmaceuticals (IONS) options were granted to Peter Reikes and at what price?

Peter N. Reikes received 10,753 non-qualified stock options with an exercise price of $75.13 per share. Each option allows him to buy one share of Ionis common stock at that exercise price once vested.

What is the vesting schedule for Peter Reikes’ Ionis (IONS) stock option grant?

The option grant vests in three equal annual installments. The first installment vests on June 4, 2027, and the award becomes fully vested and exercisable on June 4, 2029, if service-based conditions are met.

When do Peter Reikes’ Ionis Pharmaceuticals (IONS) options expire?

The non-qualified stock options granted to Peter N. Reikes expire on June 4, 2036. If not exercised by that date after vesting, the options will lapse and no longer allow the purchase of Ionis common stock.

Is Peter Reikes’ Ionis (IONS) Form 4 transaction an open-market buy or sell?

No, the Form 4 reflects a grant of 10,753 non-qualified stock options as director compensation. It does not represent an open-market purchase or sale of Ionis common stock by Peter N. Reikes.